newsfilter
← Latest News
GlobeNewswire·

Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin ("MICVO," formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and